À propos Vybion, inc.

À propos de la société

Vybion is a development stage company with platform technology for the development of a new drug class called Intrabodies. Their lead candidate for Huntington's and Azheimer's diseases is INT41 an scFv fragment that can alter gain of toxic function in Huntington's disease and block Fyn kinase binding to Tau in Alzheimer's disease. The Company operates virtually out of Monterey, CA and is focused on completing an IND enabling package for INT41.